Výsledky vyhledávání - "Vasudev Bhupathi"

A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension

Autor: Ying Jiang, Adam Simmons, Craig Hopkinson, David McDonnell, Vasudev Bhupathi, Bernard L. Silverman, Bei Yu, Jiani Yin, Christine Graham, Lauren DiPetrillo, René S. Kahn, Sergey Yagoda

Publikováno v: Schizophrenia Research. 232:45-53

Aim A combination of olanzapine and samidorphan (OLZ/SAM) is in development for the treatment of patients with schizophrenia or bipolar I disorder and is intended to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6907f444d0129dbbe4fcbbf3da905356
https://doi.org/10.1016/j.schres.2021.04.009

Zobrazit plný text záznamu

A Structured Benefit-Risk Assessment to Evaluate a Combination of Olanzapine and Samidorphan for the Treatment of Schizophrenia and Bipolar I Disorder

Autor: Brittany D. Roy, David McDonnell, Bei Yu, Christine Graham, Ying Jiang, Sergey Yagoda, Vasudev Bhupathi, Lauren DiPetrillo

Publikováno v: CNS Spectrums. 27:233-233

BackgroundA combination of olanzapine and samidorphan (OLZ/SAM) that provides the efficacy of olanzapine while mitigating weight gain was recently approved by the FDA for the treatment of schizophrenia and bipolar I disorder. To improve communication

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cefc72621fe12b35ae1d064817bb1448
https://doi.org/10.1017/s1092852922000311

Zobrazit plný text záznamu

Long-Term Antipsychotic Efficacy of Olanzapine and Samidorphan Combination in Patients With Schizophrenia: Pooled Analyses From Phase 3 Studies

Autor: Ying Jiang, Christine Graham, Vasudev Bhupathi, David McDonnell, René S. Kahn, Lauren DiPetrillo, Sergey Yagoda

Publikováno v: Biological Psychiatry. 89:S241-S242

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::30a4130cf56964e47d5d7143089c8fe8
https://doi.org/10.1016/j.biopsych.2021.02.605

Zobrazit plný text záznamu

Phase 3 Safety and Tolerability Results of the Combination Olanzapine and Samidorphan in Patients with Schizophrenia: The 1 Year ENLIGHTEN-2-Extension

Autor: Davidd McDonnell, Ying Jiang, Bernard L. Silverman, Vasudev Bhupathi, Bei Yu, Craig Hopkinson, René S. Kahn, Lauren DiPetrillo, Adam Simmons, Jiani Yin, Christine Graham

Publikováno v: CNS Spectrums. 26:155-156

ObjectiveCombination olanzapine and samidorphan (OLZ/SAM) is in development for treatment of schizophrenia and bipolar I disorder and is intended to provide the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f0772b0476c36566d71184149973db61
https://doi.org/10.1017/s1092852920002485

Zobrazit plný text záznamu

Long-Term Weight and Metabolic Effects of Olanzapine and Samidorphan Combination in Patients With Schizophrenia: Pooled Analyses From Phase 3 Studies

Autor: Bei Yu, David McDonnell, Lauren DiPetrillo, John W. Newcomer, Sergey Yagoda, Christine Graham, Vasudev Bhupathi, Ying Jiang

Publikováno v: Biological Psychiatry. 89:S242

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ee8e877e0cea93d737e0348addac6b2f
https://doi.org/10.1016/j.biopsych.2021.02.606

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání